Clinical Trials Browser

Interventional × camrelizumab × Lymphoid × Clear all

NCT06376721 2024-04-19

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03155425 2024-02-01

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2 Completed

75 enrolled 10 charts

Hodgkin Disease

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

Lymphoma, T-Cell, Peripheral

NCT05320081 2022-04-11

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Phase 2 Unknown

Lymphoma, Recurrence

NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Phase 1/2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT04514081 2020-08-18

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Phase 2 Unknown

Hodgkin Disease

NCT04233294 2020-08-14

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT04510610 2020-08-12

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 2/3 Unknown

Hodgkin Disease

NCT03363555 2020-06-18

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT04337606 2020-04-07

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin

NCT04239170 2020-01-23

Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT03250962 2019-04-01

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease, Recurrence

NCT03701022 2018-10-09

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell